Association of Metabolic Syndrome with Adverse Outcomes in Patients with Stable Coronary Artery Disease: A Meta-Analysis

Abstract

A consensus has not been reached on the association of metabolic syndrome (MetS) with adverse outcomes in patients with stable coronary artery disease (CAD). The purpose of this systematic review and meta-analysis was to summarize the prognostic implication of MetS in patients with stable CAD. We comprehensively searched articles indexing in PubMed and Embase databases until August 14, 2022. Original studies investigating the association of MetS with adverse outcomes in patients with stable CAD were included. Seven studies including 32 736 patients with stable CAD were identified. Depending on the definition of MetS, the reported prevalence of MetS ranged from 23.4% to 63%. Meta-analysis showed that patients with MetS conferred an increased risk of all-cause mortality [risk ratio (RR) 1.22; 95% confidence intervals (CI) 1.15–1.19], cardiovascular mortality (RR 1.49; 95% CI 1.16–1.92), and MACEs defined by death, myocardial infarction, revascularization, cardiac arrest, or angina admission (RR 1.47; 95% CI 1.20–1.79), respectively. Leave-one-out sensitivity analysis indicated the robustness of the value of MetS in prediction of all-cause mortality. MetS may be an independently predictor of adverse outcomes in patients with stable CAD. However, future studies are required to consolidate the current evidence due to the small number of studies included.

Key words

metabolic syndrome - stable coronary artery disease - cardiovascular mortality - all-cause mortality

• References

• 1 Fox KAA, Metra M, Morais J. et al. The myth of ‘stable’ coronary artery disease. Nat Rev Cardiol 2020; 17: 9-21
• 2 Bertolone DT, Gallinoro E, Esposito G. et al. Contemporary management of stable coronary artery disease. High Blood Press Cardiovasc Prev 2022; 29: 207-219
• 3 Ruiz Ortiz M, Ogayar C, Romo E. et al. Long-term survival in elderly patients with stable coronary disease. Eur J Clin Invest 2013; 43: 774-782
• 4 Vidal-Petiot E, Ford I, Greenlaw N. et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet 2016; 388: 2142-2152
• 5 Braun MM, Stevens WA, Barstow CH. Stable coronary artery disease: treatment. Am Fam Physician 2018; 97: 376-384
• 6 Yang Y, Shen H, Jin Z. et al. Association between metabolic syndrome and all-cause mortality in patients with acute coronary syndrome: a meta-analysis. Horm Metab Res 2021; 53: 257-263
• 7 Varounis C, Rallidis LS, Franco OH. et al. Prevalence of metabolic syndrome and association with burden of atherosclerotic disease in patients with stable coronary artery disease. Curr Med Res Opin 2016; 32: 1175-1181
• 8 Aguilar D, Fisher MR, O’Connor CM. et al. Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease. Am Heart J 2006; 152: 298-304
• 9 Daly CA, Hildebrandt P, Bertrand M. et al. Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial. Heart 2007; 93: 1406-1411
• 10 Kragelund C, Kober L, Faber J. et al. Metabolic syndrome and mortality in stable coronary heart disease: relation to gender. Int J Cardiol 2007; 121: 62-67
• 11 Lopes NH, Paulitsch FS, Pereira AC. et al. Impact of metabolic syndrome on the outcome of patients with stable coronary artery disease: 2-year follow-up of the MASS II study. Coron Artery Dis 2008; 19: 383-388
• 12 Arbel Y, Havakuk O, Halkin A. et al. Relation of metabolic syndrome with long-term mortality in acute and stable coronary disease. Am J Cardiol 2015; 115: 283-287
• 13 Liberati A, Altman DG, Tetzlaff J. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62: e1-e34
• 14 Wells G, Shea B, O‘Connell D. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp Assessed September 19, 2022
• 15 Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101
• 16 Egger M, Davey Smith G, Schneider M. et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
• 17 Younis A, Younis A, Tzur B. et al. Metabolic syndrome is independently associated with increased 20-year mortality in patients with stable coronary artery disease. Cardiovasc Diabetol 2016; 15: 149
• 18 Mayer O, Bruthans J, Seidlerova J. et al. Prospective study of metabolic syndrome as a mortality marker in chronic coronary heart disease patients. Eur J Intern Med 2018; 47: 55-61
• 19 Lau J, Ioannidis JP, Terrin N. et al. The case of the misleading funnel plot. BMJ 2006; 333: 597-600
• 20 Tie HT, Shi R, Li ZH. et al. Risk of major adverse cardiovascular events in patients with metabolic syndrome after revascularization: A meta-analysis of eighteen cohorts with 18,457 patients. Metabolism 2015; 64: 1224-1234